A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...
Whole-body diffusion-weighted MRI scans may be as effective as traditional PET-CT scans for staging cancer tumors in children and young adults without exposing patients to ionizing radiation, ...
Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy. Prevalence of treatment-acquired homozygous ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...
Efforts to improve cancer imaging technologies are crucial for diagnosing and treating the disease effectively. This transition from experimental to clinical use requires bridging the gap between ...
FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results